Fagron Acquires Pharmavit Europe for €68M to Bolster Nutraceutical Leadership
Event summary
- Fagron NV completed the acquisition of Pharmavit Europe for €68 million on February 26, 2026.
- Pharmavit Europe generates €62 million in annual revenue with an EBITDA margin below Fagron’s group average.
- The deal strengthens Fagron’s position in nutraceutical ingredients across EMEA, adding repackaging and own-brand capabilities.
- Fagron expects to realize synergies over the next 18 to 24 months through operational excellence and commercial collaboration.
The big picture
Fagron’s acquisition of Pharmavit Europe aligns with the growing demand for preventive healthcare and lifestyle-focused nutrition. The deal expands Fagron’s nutraceutical ingredients portfolio, positioning it to capitalize on structural trends in the EMEA region. With €68 million invested, Fagron aims to enhance its market leadership while improving operational efficiencies.
What we're watching
- Integration Challenges
- How Fagron will improve Pharmavit Europe’s EBITDA margin below group average through operational excellence.
- Cross-Selling Potential
- The pace at which Fagron leverages Pharmavit Europe’s capabilities for portfolio expansion across its global footprint.
- Market Dynamics
- Whether Fagron can sustain growth in the nutraceutical segment amid increasing competition in EMEA.
Related topics